

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN PHARMA**

**复星医药**

**上海復星醫藥（集團）股份有限公司**

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

## **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”) hereby announces that a meeting of the Board will be held on Tuesday, 29 April 2025, for the purposes of, among other things, considering and approving the first quarterly results of the Company and its subsidiaries for the three months ended 31 March 2025 and its publication.

By order of the Board

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Wu Yifang**

*Chairman*

Shanghai, the PRC

15 April 2025

*As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing,; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.*

\* For identification purposes only